Despite significant improvement in early post-transplant survival rates, the pressing need for continuing refinement of clinical immunosuppressive protocols is emphasized by the morbidity and annual attrition rate of 3-5% still observed in chronically treated allograft recipients. The objective of this project is to evaluate systematically the mechanisms of immune modulation induced by monoclonal antibodies (mAbs) or cytokine antagonists and to provide a final pre-clinical proving ground for new protocols employing these agents. To date, most Mabs have been added to clinical protocols on an empirical basis. In view of the large numbers of these agents now available, it is essential that a systematic pre-clinical approach to their evaluation be continued. The immediate goal of this project is to refine chronically administered regimens so that effective, yet selective, depression of the immune response is provided. Instrinsic to this goal is a more thorough clarification of the roles that various mononuclear cell populations play in either the rejection or the """"""""down regulation"""""""" response to an allograft and the importance of factors, such as cell subset reactivity or cell clearing efficacy, which are most important in determining the immunosuppressive activity of mAbs. With this approach, it should be possible to identify the most appropriate targets for new, highly selective clinical protocols which employ """"""""novel"""""""" mAbs such as chimeric mouse-human molecules or bi- specific antibodies chosen for their reactivity only with """"""""activated"""""""" or other cell subsets. These studies are planned with the expectation that they will lead to the ultimate goal of providing long-term donor- specific unresponsiveness which can be induced by only a limited course of treatment in the peri-transplant period.
| Newton, Ryan H; Shrestha, Sharad; Sullivan, Jenna M et al. (2018) Maintenance of CD4 T cell fitness through regulation of Foxo1. Nat Immunol 19:838-848 |
| Hotta, Kiyohiko; Oura, Tetsu; Dehnadi, Abbas et al. (2018) Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation. Transplantation 102:e128-e136 |
| Robinson, Kortney A; Orent, William; Madsen, Joren C et al. (2018) Maintaining T cell tolerance of alloantigens: Lessons from animal studies. Am J Transplant 18:1843-1856 |
| Sasaki, Hajime; Oura, Tetsu; Spitzer, Thomas R et al. (2018) Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. Hum Immunol 79:258-265 |
| Tanimine, Naoki; Turka, Laurence A; Priyadharshini, Bhavana (2018) Navigating T-Cell Immunometabolism in Transplantation. Transplantation 102:230-239 |
| Michel, S G; Madariaga, M L L; LaMuraglia 2nd, G M et al. (2018) The effects of brain death and ischemia on tolerance induction are organ-specific. Am J Transplant 18:1262-1269 |
| Smith, R N; Adam, B A; Rosales, I A et al. (2018) RNA expression profiling of renal allografts in a nonhuman primate identifies variation in NK and endothelial gene expression. Am J Transplant 18:1340-1350 |
| Chatterjee, Debanjana; Moore, Carolina; Gao, Baoshan et al. (2018) Prevalence of polyreactive innate clones among graft--infiltrating B cells in human cardiac allograft vasculopathy. J Heart Lung Transplant 37:385-393 |
| Gonzalez-Nolasco, Bruno; Wang, Mengchuan; Prunevieille, Aurore et al. (2018) Emerging role of exosomes in allorecognition and allograft rejection. Curr Opin Organ Transplant 23:22-27 |
| Smith, R N; Matsunami, M; Adam, B A et al. (2018) RNA expression profiling of nonhuman primate renal allograft rejection identifies tolerance. Am J Transplant 18:1328-1339 |
Showing the most recent 10 out of 305 publications
